PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Leaf extracts significantly improved memory scores and reduced amnesia induced by scopolamine and diazepam in mice [PMID:18844259]; ethanolic and aqueous extracts improved cognitive impairment in Alloxan-induced diabetic rats [PMID:36937470].
Alkaloid enriched fractions ameliorated high-fat diet-induced obesity and metabolic complexities in mice [PMID:38878841]; reported anti-obesity and anti-diabetic activity in in vitro and in vivo studies [PMID:39253925].
Mahanine and leaf extracts demonstrated cytotoxic effects and protective potential against DMBA-induced breast carcinogenesis in rats [PMID:29175114, PMID:37678421, PMID:34566312].
Ethanolic leaf extract improved the lipid profile of rats fed with cholesterol-enriched diets [PMID:38243555].
Leaf extract showed cardioprotective potential against doxorubicin-induced cardiotoxicity in rats [PMID:32308710].
Evidence summary
PubMed sources
- 1.PMID: 39253925 (2024) — Murraya koenigii (L.) Spreng. as a Natural Intervention for Diabesity: A Review. · Current pharmaceutical design
- 2.PMID: 35215300 (2022) — Multi-Target Approach of Murraya koenigii Leaves in Treating Neurodegenerative Diseases. · Pharmaceuticals (Basel, Switzerland)
- 3.PMID: 31991665 (2020) — Medicinal Profile, Phytochemistry, and Pharmacological Activities of Murraya koenigii and its Primary Bioactive Compounds. · Antioxidants (Basel, Switzerland)
- 4.PMID: 29175114 (2018) — Phytochemical portfolio and anticancer activity of Murraya koenigii and its primary active component, mahanine. · Pharmacological research
- 5.PMID: 34754314 (2021)